Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ5 | P48544 | 6/20 | 0.53 |
| ▸ | KCNJ3 | P48549 | 6/20 | 0.53 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.45 |
| ▸ | PRKX | P51817 | 1/20 | 0.45 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.45 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.42 |
| ▸ | ANO1 | Q5XXA6 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30285655 | 1.00 | KCNJ5 (0.53) | KCNJ5KCNJ3KCNJ6SMN1; SMN2ALDH1A1 | |
| SCHEMBL30285736 | 0.92 | SMN1; SMN2 (0.46) | KCNJ5KCNJ3SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL26186457 | 0.92 | SMN1; SMN2 (0.46) | KCNJ5KCNJ3SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL30285791 | 0.92 | KCNJ5 (0.49) | KCNJ5KCNJ3KCNJ6ALDH1A1CLK2 | |
| SCHEMBL26186462 | 0.92 | KCNJ5 (0.49) | KCNJ5KCNJ3KCNJ6ALDH1A1CLK2 | |
| SCHEMBL24173310 | 0.89 | RECQL (0.51) | SMN1; SMN2MAPTKMT2AMEN1ANO1 | |
| SCHEMBL30285581 | 0.89 | RECQL (0.51) | SMN1; SMN2MAPTKMT2AMEN1ANO1 | |
| SCHEMBL30285528 | 0.89 | KCNJ5 (0.50) | KCNJ5KCNJ3KCNJ6SMN1; SMN2ALDH1A1 | |
| SCHEMBL26186450 | 0.89 | KCNJ5 (0.50) | KCNJ5KCNJ3KCNJ6SMN1; SMN2ALDH1A1 | |
| SCHEMBL30285692 | 0.89 | KCNJ5 (0.56) | KCNJ5KCNJ3KCNJ6ALDH1A1CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115996911-A | Substituted N-phenylacetamides having P2X4 receptor antagonistic activity | 拜耳公司 | 2023-04-21 | — | — | CN | claimed |
| US-20230270729-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | US | disclosed |
| US-20230270729-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | US | disclosed |
| US-20230257351-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-17 | — | — | US | disclosed |
| US-20230257351-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-17 | — | — | US | disclosed |
| CN-115996911-A | Substituted N-phenylacetamides having P2X4 receptor antagonistic activity | 拜耳公司 | 2023-04-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257351-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | P2RX2, P2RX5, P2RX3 | KCNJ5 452/4885KCNJ3 610/4885KCNJ6 608/4885 |
| US-20230270729-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS | P2RX2, P2RX4, P2RX5 | KCNJ5 2411/4885KCNJ3 2969/4885KCNJ6 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.